Home » Illumina

Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

Jul 12, 2018

Illumina, OrigiMed Collaborate to Develop Cancer Assays

OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.

Jun 08, 2018

With Edico Buy, Illumina to Focus on Rare Disease Diagnostic Sequencing Market

Premium

Illumina is working on further reducing turnaround time of the analysis and on detecting structural variants and repeat expansions.

Jun 08, 2018

Illumina Extends Supply Agreement With Foundation Medicine, Collaborates with PerkinElmer

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

May 15, 2018

Illumina Acquires Edico Genome

Illumina said the acquisition will help enable a standardized process for sequencing and analysis and speed up the time it take to get a result.

May 10, 2018

CareDx Q1 Revenues Up 21 Percent

The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.

May 09, 2018

CareDx Licenses Illumina NGS Transplant Clinical Application Products

CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.

May 08, 2018

Illumina Ventures, Arch Venture Partners Invest in Luna DNA

Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.

May 01, 2018

CanSeq150 Sets Out to Sequence 150 Diverse Species

Premium

The effort aims to sequence at least 150 animals, plants, and microbes selected for their potential benefits to Canada in the next three years.

Apr 27, 2018

Illumina Names Five New Startups for Accelerator Program

Illumina launched the accelerator program in 2014 to provide biotech startups with investment capital, genomics expertise, and other resources.

Apr 25, 2018

Illumina Predicts Recent Regulatory, Reimbursement Decisions Will Drive Oncology, Consumer Markets

Premium

The company said that recent regulatory and reimbursement decisions have been favorable and will help spur adoption of clinical NGS testing.

Pages

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.